Business & Economics Books:

The Biotech Age: The Business of Biotech and How to Profit From It

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Paperback / softback
$48.99
Available from supplier

The item is brand new and in-stock with one of our preferred suppliers. The item will ship from a Mighty Ape warehouse within the timeframe shown.

Usually ships in 3-4 weeks

Buy Now, Pay Later with:

Afterpay is available on orders $100 to $2000 Learn more

Availability

Delivering to:

Estimated arrival:

  • Around 28 Jun - 10 Jul using International Courier

Description

Since The Coming BioTech Age was published in 1999, much has changed in this fast-moving, volatile industry. Furthermore, media attention on biotech, especially ethical and legislative issues, has increased several times over. Biotech companies are featured regularly in business publications and general interest magazines and newspapers are running stories on cloning and stem cell research on an almost daily basis. Major developments that have taken place since the book was published, The human genome was mapped by Celera Genomics in June, 2000, well ahead of schedule, just a few months after a rough draft was finished. Stem cell research has become front-page news, with debates in Congress, the White House, and the public forums being hotly contested. The politically powerful "Right to Life" camp has split down the middle on the issue. Funding and investment in biotech have increased at a rapid pace, with the tech meltdown having little effect on the biotech environment. Market capitalization increased from USD138 billion when the book was written to over USD330 billion in 2001, despite declines in the overall markets. There are now more than 350 biotech drugs and vaccines in clinical trials, targeting more than 200 diseases. Total sales and revenues in at biotech companies both increased over 10 percent in the year following the book's publishing, despite the ongoing recession. Medical biotech companies have gained much more clout in negotiations with Big Pharma, especially after raising a record USD31 billion in 2000. In 2001, GM crops comprised 74 percent of all soybeans grown in the US, 71 percent of all cotton, and 32 percent of all corn. In 2000, the US Supreme Court upheld the rights of companies to patent hybrid and genetically modified plants. All of the above and more - including a new introduction and conclusion - will be covered in this completely revised and updated paperback edition.

Author Biography

McGraw-Hill authors represent the leading experts in their fields and are dedicated to improving the lives, careers, and interests of readers worldwide
Release date Australia
April 1st, 2003
Audience
  • Professional & Vocational
Country of Publication
United States
Edition
2nd edition
Imprint
McGraw-Hill Professional
Pages
256
Publisher
McGraw-Hill Education - Europe
Dimensions
150x226x18
ISBN-13
9780071414890
Product ID
10770674

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

Filed under...